Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 4/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | HTR6 | P50406 | 2/20 | 0.49 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.49 |
| ▸ | HTR3B | O95264 | 2/20 | 0.49 |
| ▸ | HTR3A | P46098 | 2/20 | 0.49 |
| ▸ | HTR5A | P47898 | 2/20 | 0.49 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.49 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | NCF1 | P14598 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | HTR1D | P28221 | 1/20 | 0.49 |
| ▸ | HTR1B | P28222 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15066499 | 0.98 | BACE1 (0.54) | BACE1HSD17B10HTR6HTR3EHTR3B | |
| Hydrochloric Acid SCHEMBL5501060 | 0.97 | BACE1 (0.53) | BACE1HSD17B10HTR6HTR3EHTR3B | |
| SCHEMBL17144366 | 0.87 | HSD17B10 (0.55) | HSD17B10TSHRMAOAHPGDKDM4E | |
| SCHEMBL5867498 | 0.86 | MAOA (0.56) | HSD17B10MAOAHPGDKDM4EALDH1A1 | |
| SCHEMBL15068505 | 0.80 | ALDH1A1 (0.43) | BACE1HSD17B10CYP1A2MAOAHPGD | |
| SCHEMBL15066938 | 0.80 | ALDH1A1 (0.43) | BACE1HSD17B10CYP1A2MAOAHPGD | |
| SCHEMBL9229724 | 0.80 | HTR6 (0.48) | BACE1HSD17B10HTR6HTR3EHTR3B | |
| SCHEMBL15230293 | 0.80 | LATS1 (0.45) | BACE1CYP1A2HTR1ACYP2D6NCF1 | |
| SCHEMBL3237749 | 0.79 | BCHE (0.49) | BACE1HSD17B10HTR6HTR3EHTR3B | |
| SCHEMBL27476454 | 0.79 | HTR6 (0.47) | BACE1HSD17B10HTR6HTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102050809-B | Chemokine-like factor 1 (CKLF1)/C chemokine receptor 4 (CCR4) interaction-antagonistic 3-peperazinyl coumarin derivatives | INST MATERIA MEDICA CAMS | 2014-12-17 | — | — | CN | claimed |
| CN-102050809-A | Chemokine-like factor 1 (CKLF1)/C chemokine receptor 4 (CCR4) interaction-antagonistic 3-peperazinyl coumarin derivatives | INST MATERIA MEDICA CAMS | 2011-05-11 | — | — | CN | claimed |
| CN-114096250-B | Therapies for erythropoiesis protoporphyria (EPP) and X-linked protoporphyria (XLP) | 匹兹堡大学 联邦高等教育系统 | 2025-01-14 | — | — | CN | disclosed |
| CN-114096250-A | Novel therapy for erythropoietic protoporphyrinopathy (EPP) and X-linked protoporphyrinopathy (XLP) | 匹兹堡大学联邦高等教育系统 | 2022-02-25 | — | — | CN | disclosed |
| US-RE47689-E1 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-9617268-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20150119380-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-30 | — | — | US | disclosed |
| CN-102050809-B | Chemokine-like factor 1 (CKLF1)/C chemokine receptor 4 (CCR4) interaction-antagonistic 3-peperazinyl coumarin derivatives | INST MATERIA MEDICA CAMS | 2014-12-17 | — | — | CN | disclosed |
| CN-102050809-B | Chemokine-like factor 1 (CKLF1)/C chemokine receptor 4 (CCR4) interaction-antagonistic 3-peperazinyl coumarin derivatives | INST MATERIA MEDICA CAMS | 2014-12-17 | — | — | CN | disclosed |
| CN-102050809-B | Chemokine-like factor 1 (CKLF1)/C chemokine receptor 4 (CCR4) interaction-antagonistic 3-peperazinyl coumarin derivatives | INST MATERIA MEDICA CAMS | 2014-12-17 | — | — | CN | disclosed |
| EP-2797592-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC Therapeutics, Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| WO-2013101974-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| US-20120052005-A1 | COMBINATION THERAPY TO IMPROVE DRUG EFFICIENCY | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-03-01 | — | — | US | disclosed |
| CN-102050809-A | Chemokine-like factor 1 (CKLF1)/C chemokine receptor 4 (CCR4) interaction-antagonistic 3-peperazinyl coumarin derivatives | INST MATERIA MEDICA CAMS | 2011-05-11 | — | — | CN | disclosed |
| CN-102050809-A | Chemokine-like factor 1 (CKLF1)/C chemokine receptor 4 (CCR4) interaction-antagonistic 3-peperazinyl coumarin derivatives | INST MATERIA MEDICA CAMS | 2011-05-11 | — | — | CN | disclosed |
| CN-102050809-A | Chemokine-like factor 1 (CKLF1)/C chemokine receptor 4 (CCR4) interaction-antagonistic 3-peperazinyl coumarin derivatives | INST MATERIA MEDICA CAMS | 2011-05-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119380-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, RBM17, RBM22 | BACE1 1158/4885HSD17B10 3141/4885HTR6 3148/4885 |
| US-20120052005-A1 | COMBINATION THERAPY TO IMPROVE DRUG EFFICIENCY | ABCG2, ABCB1, ABCC1 | BACE1 3185/4885HSD17B10 826/4885HTR6 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.